- Home
- EXFY vs LRMR Comparison
EXFY vs LRMR Comparison
Compare EXFY & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- LRMR
- Stock Information
- Founded
- EXFY 2008
- LRMR N/A
- Country
- EXFY United States
- LRMR United States
- Employees
- EXFY N/A
- LRMR N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- LRMR Health Care
- Exchange
- EXFY Nasdaq
- LRMR Nasdaq
- Market Cap
- EXFY 206.1M
- LRMR 191.4M
- IPO Year
- EXFY 2021
- LRMR N/A
- Fundamental
- Price
- EXFY $2.30
- LRMR $3.38
- Analyst Decision
- EXFY Strong Buy
- LRMR Strong Buy
- Analyst Count
- EXFY 3
- LRMR 7
- Target Price
- EXFY $4.75
- LRMR $17.86
- AVG Volume (30 Days)
- EXFY 1.1M
- LRMR 1.3M
- Earning Date
- EXFY 08-07-2025
- LRMR 08-06-2025
- Dividend Yield
- EXFY N/A
- LRMR N/A
- EPS Growth
- EXFY N/A
- LRMR N/A
- EPS
- EXFY N/A
- LRMR N/A
- Revenue
- EXFY $141,775,000.00
- LRMR N/A
- Revenue This Year
- EXFY $7.77
- LRMR N/A
- Revenue Next Year
- EXFY $5.45
- LRMR N/A
- P/E Ratio
- EXFY N/A
- LRMR N/A
- Revenue Growth
- EXFY N/A
- LRMR N/A
- 52 Week Low
- EXFY $1.45
- LRMR $1.61
- 52 Week High
- EXFY $4.13
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- EXFY 46.18
- LRMR 63.62
- Support Level
- EXFY $2.41
- LRMR $3.30
- Resistance Level
- EXFY $2.61
- LRMR $3.57
- Average True Range (ATR)
- EXFY 0.15
- LRMR 0.30
- MACD
- EXFY -0.00
- LRMR 0.03
- Stochastic Oscillator
- EXFY 35.13
- LRMR 85.93
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.